VIENNA—Latest research on breast cancer prevention was reported at the 20125 St Gallen breast cancer conference in a session concluded by Jack Cuzick, PhD, Director of the Wolfson Institute of Preventive Medicine and Head of the Centre for Cancer Prevention at Queen Mary, University of London. Oncology Times reporter Sarah Maxwell began by asking him about the IBIS I and II studies—using drugs affecting the estrogen receptor—and about IBIS III using aromatase inhibitor, bisphosphonate and metformin for primary prevention.
You may also like...
Chronic myeloid leukaemia: third generation TKI, ponatinib, succeeds against the T 315 I mutation 18 Dec, 2012 Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes 10 Dec, 2007 CD8+ Cell Infiltration for Prognosis in Non-Small Cell Lung Cancer; Checkpoint Inhibition 2nd/3rd-line in Mesothelioma 26 Apr, 2015 Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia 19 Jan, 2018
- Previous story Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer
- Next story New Strategies for Preventing ER-Negative Breast Cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014